Belgium’s TiGenix (Euronext Brussels: TIG) has released positive 52-week data from the Phase III ADMIRE-CD trial investigating Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease.
The data show that Cx601 maintained long-term remission and that a single injection of the candidate was statistically superior to control.
The company says the one-year data also confirmed the favorable safety and tolerability profile of Cx601 reported at week 24.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze